Orthocell Limited (ASX:OCC) was down 1.3% during trading on Friday . The stock traded as low as A$0.37 ($0.26) and last traded at A$0.38 ($0.27), approximately 275,251 shares changed hands during mid-day trading. The stock had previously closed at A$0.38 ($0.27).
The business has a 50 day moving average price of A$0.44. The company has a market cap of $57.36 million and a price-to-earnings ratio of -7.65.
About Orthocell (ASX:OCC)
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and Poland. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment resistant tendon injuries.
Further Reading: Oversold
Receive News & Ratings for Orthocell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthocell and related companies with MarketBeat.com's FREE daily email newsletter.